Calquence

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
PSUSA/10887 /202104	Periodic Safety Update EU Single assessment - acalabrutinib	02/12/2021	n/a		PRAC Recommendation - maintenance
II/0004	Submission of the final report of the nonclinical Study 20266648 (5336BV) (Acalabrutinib: Neutral Red Uptake Phototoxicity Assay in BALB/c 3T3 Mouse	11/11/2021		SmPC	For more information, please refer to the Summary of Product Characteristics.

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	Fibroblasts), in response to the CHMP recommendation to submit results from a modified 3T3 NRU phototoxicity study with adjusted wavelengths. SmPC sections 4.4 and 5.3 were updated accordingly. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority				
IA/0010	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	21/10/2021	n/a		
II/0007	Update of section 4.5 of the SmPC following submission of the final report from ACE-HV-114, an open-label, fixed sequence study in healthy subjects to assess the pharmacokinetics of acalabrutinib and its active metabolite, ACP-5862, when administered alone and in combination with moderate CYP3A4 inhibitors fluconazole or isavuconazole. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	30/09/2021		SmPC	Small increases in acalabrutinib maximum concentration (Cmax) and Area Under the Curve (AUC) and decreases of the Cmax and AUC of its active metabolite ACP-5862 were obserevd when acalabrutinib was co-administed with moderate CYP3A inhibitors in helathy subjects. No dose adjustment of acalabrutinib is required when used in combination with moderate CYP3A inhibitors but patients should be monitored closely for adverse reactions.

II/0006	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	30/09/2021	n/a		
II/0005	Submission of the final report from study XS-1468 to further characterise the plasma protein binding of acalabrutinib and its metabolite ACP-5862 in different species. Section 5.2 of the SmPC is updated accordingly to reflect the new plasma protein binding data. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	24/06/2021		SmPC	
IAIN/0003	C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority	18/02/2021	n/a		
IA/0002	B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer	07/01/2021	n/a		
IAIN/0001	B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer	21/12/2020	n/a		